Avance Biosciences’ NGS Center of Excellence delivers comprehensive sequencing solutions, including short-read, long-read, and advanced single-cell platforms. Our regulatory-compliant workflows support biologics, gene, and cell therapy programs with high-quality data, enabling informed development...
Avance Biosciences™ will exhibit at BPI International 2025 in Boston, showcasing our end-to-end analytical and testing services for biologics, cell, and gene therapies. Visit booth 1508 to learn about our NGS Center of Excellence, offering advanced sequencing, on/off-target detection, and gene editing safety assessments...
To support IND-enabling studies, a biotech company needed precise measurement of in vivo gene-editing efficiency in preclinical rat tissues. Avance Biosciences delivered a fully validated NGS amplicon sequencing assay capable of detecting edits as low as 1%, enabling accurate quantification across multiple tissues and guiding data-driven development decisions.
When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Avance Biosciences is proud to announce the partial commissioning of our new GMP facility at 5500 Northwest Central Drive in Houston, Texas. Effective July 21, 2025, select Biologics Quality Control services, including Microbiology and Sanger sequencing, will transition from our West Little York site to this new location. Please begin shipping samples directly to the new facility as we continue to expand our capabilities to better serve our clients.
Our new blog series explore how cutting-edge NGS technologies are being applied to solve real-world challenges in biopharmaceutical development. Follow along for insights into assay strategies, platform selection, and the measurable impact of our scientific approach...
Avance Biosciences™ will not only be exhibiting (booth #516), but also presenting two posters as part of the Next-Generation Analytical Methods program: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq & Digitally Secure Sequencing: Implementing Part 11-Ready NGS Data Security in a CRO Environment...
Avance Biosciences now offers LC-MS/MS services to support precise bioanalytical testing for small molecules, peptides, oligonucleotides, and biomarkers, enhancing drug development with advanced PK/PD, impurity profiling, and targeted proteomics capabilities...
Avance Biosciences™ is proud to announce its participation in the Bioprocessing Summit 2025 in Boston, MA. Visit Booth #516 to learn how our GLP- and GMP-compliant analytical services support the development and manufacturing of biologics, cell and gene therapies, and advanced biotherapeutics...
Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities...
